BioMarin Pharmaceutical Inc
Abrir
SetorSaúde
56.08 0.21
Visão Geral
Variação de preço das ações
24h
Mín
55.28
Máximo
56.3
Rendimento | -34M 106M |
|---|---|
Vendas | -108M 766M |
P/E Médio do Setor | 40.684 49.052 |
EPS | 0.76 |
Margem de lucro | 13.773 |
Funcionários | 3,221 |
EBITDA | 177M 173M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +55.5% upside |
Próximos Ganhos | 3 de ago. de 2026 |
|---|
Capitalização de Mercado | 531M 11B |
|---|---|
Abertura anterior | 55.87 |
Fecho anterior | 56.08 |
Sentimento de Notícias
By Acuity
50%
50%
146 / 342 Ranking em Healthcare
BioMarin Pharmaceutical Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.